Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial

Transplantation

Volumn 90, Issue 12, 2010, Pages 1581-1589

  Gullestad, Lars ^a,b   Mortensen, Svend Aage ^c   Eiskjær, Hans ^d   Riise, Gerdt C ^e   Mared, Lena ^f   Bjørtuft, Øystein ^a   Ekmehag, Björn ^f   Jansson, Kjell ^g   Simonsen, Svein ^a   Gude, Einar ^a   Rundqvist, Bengt ^e   Fagertun, Hans E ^h   Solbu, Dag ⁱ   Iversen, Martin ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Rigshospitalet   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h Capturo AS   (Norway)

ⁱ Medical Department   (Norway)

Author keywords

Certican; CNI; Cyclosporine A; Everolimus; Renal impairment; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG BIOPSY; LUNG EMBOLISM; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; STROKE; SURGICAL PATIENT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; SIROLIMUS;

EID: 78650832714     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fd01b7     Document Type: Article

References (21)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of nonrenal organ. N Eng J Med 2003; 349: 931.
2. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated endstage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 1997; 63: 664.
3. Hornum M, Burton CM, Iversen M, et al. Decline in 51Cr-labelled EDTA measured glomerular filtration rate following lung transplantation. Nephrol Dial Transplant 2007; 22: 3616.
4. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
5. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacologic properties in vitro and in vivo. Transplantation 1997; 64: 36.
6. Schuurman J-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation 1997; 64: 32.
7. Ross H, Pflugfelder P, Haddad H, et al; CADENCE Study Group. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008; 27: 197.
8. Ross H, Pflugfelder P, Haddad H, et al. Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: A pilot study. Transpl Int 2010; 23: 31.
9. Potena L, Bianchi IG, Magnani G, et al. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: A randomized study. Transplantation 2010; 89: 263.
10. Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant patients. Transpl Immunol 2006; 16: 46.
11. Boffini M, Sansone F, Patanè F, et al. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience. Transplant Proc 2009; 41: 1349.
12. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial. Transplantation 2010; 89: 864.
13. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Tenth official pediatric lung and heart/lung transplantation report-2009. J Heart Lung Transplant 2009; 28: 1007.
14. Aurora P, Edwards LB, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: Tenth official pediatric lung and heart/lung transplantation report-2009. J Heart Lung Transplant 2009; 28: 1023.
15. Gude E, Gullstad L, Arora S, et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010; 29: 641.
16. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
17. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study. Am J Transplant 2009; 9: 1115.
18. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194.
19. Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.
20. Kaplan B, Meier-Kriesche H-U, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005; 19: 551.
21. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100.